Comparative study of the side-effect profile between clozapine and non-clozapine patients
| Autor: | F. Dinamarca, J. R. Fortuny Olive, L. Ortiz Sanz, P. Salgado Serrano, E. Jove Badia, A. Mane Santacana, S. Ramos Perdigues, X. Valiente Torrelles, V. Pérez Solá |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Side effect business.industry medicine.drug_class medicine.medical_treatment Overweight medicine.disease Psychiatry and Mental health Schizophrenia Internal medicine medicine Anticholinergic medicine.symptom Metabolic syndrome Antipsychotic business Psychiatry Adverse effect Clozapine medicine.drug |
| Zdroj: | European Psychiatry. 33:s261-s261 |
| ISSN: | 1778-3585 0924-9338 |
| DOI: | 10.1016/j.eurpsy.2016.01.667 |
| Popis: | IntroductionFor resistant schizophrenia, the only approved treatment is clozapine. However, clozapine is underused, mainly due to its wide range of side-effects. Secondary effects differ amongst antipsychotics (Leucht et al., 2009). Despite that there is no good evidence that combined antipsychotics offer any advantage over the use of a single antipsychotic, combination increases the frequency of adverse events (Maudsley guidelines).ObjectivesTo compare the side-effect profile between clozapine and non-clozapinepatients.AimsTo provide evidence that clozapine patients do not show a worse side-effects profile.MethodsWe cross-sectionally analysed all patients from a Spanish long-term mental care facility (n = 139). Schizophrenic/schizoaffective patients were selected (n = 118) and their treatment was assessed, 31 patients used clozapine. We paired clozapine and non-clozapine patients by sex and age and assessed antipsychotic side effects and possible confounder variables.ResultsOur sample was 27 clozapine patients and 29 non-clozapine patients. 67,9% were male with a mean age of 51.3 (SD 9.6) years. For continuous variables: age, BMI, waist/hip, cholesterol, TG, glucose, prolactin, heart-rate, blood pressure, sleeping hours, the only statistical differences found were lower heart-rate (P = 0.001) in clozapine group and higher salivation subscale of SAS (P = 0.002) in clozapine group. For discrete variables: monotherapy, obesity, overweight, metabolic syndrome or possible confounders as propranolol, laxative, diet, antiglycemiant or insulin, fibrates or statins, antihypertensive or anticholinergic, no statistical differences were found.ConclusionsWe did not find differences in cardiometabolic parameters, which are the main barrier to prescribing clozapine, probably due to the concomitant use of other drugs in both groups.Disclosure of interestThe authors have not supplied their declaration of competing interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|